Skip to main content
Evidence Snapshot

Tissue-type plasminogen activator

CHEMBL1873 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-12T23:16:29Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1873
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tissue-type plasminogen activator as ChEMBL target CHEMBL1873, mapped to UniProt P00750. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tissue-type plasminogen activator
SINGLE PROTEIN · Homo sapiens
As of 2026-09-12
ChEMBL target ID
CHEMBL1873
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-12
www.ebi.ac.uk
UniProt accession
P00750
Tissue-type plasminogen activator
UniProt accession via ChEMBL component mapping As of 2026-09-12
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-12
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Tissue-type plasminogen activator matters

As of 2026-09-12

Tissue-type plasminogen activator is reviewed as Tissue-type plasminogen activator (UniProt P00750); Tissue-type plasminogen activator shows approved-linked disease relevance led by myocardial infarction. 5 more disease programs remain visible in the same review block.; 3 linked drugs keep this evidence frame grounded.; the current evidence base includes 2 approved drugs, 1434 compounds, and 244 assays, with lead potency reaching pChEMBL 9.5.

Disease context
myocardial infarction

Tissue-type plasminogen activator shows approved-linked disease relevance led by myocardial infarction. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ALTEPLASE, RETEPLASE, TENECTEPLASE.

Start review with myocardial infarction because it currently carries approved-linked support. Linked drugs include ALTEPLASE, RETEPLASE, TENECTEPLASE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 3 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 2 approved drugs, 1434 compounds, and 244 assays for this target. The dominant activity type is IC50. CHEMBL439678 is the current potency anchor at pChEMBL 9.5.

Use CHEMBL439678 as the tractability anchor when discussing potency (pChEMBL 9.5).

Activity source · ChEMBL 36 via Core Engine
2 approved pChEMBL 9.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Tissue-type plasminogen activator matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P00750, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why myocardial infarction is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1434
Total Compounds
244
Total Assays
2
Approved Drugs
IC50: 768.0, KI: 499.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL439678
 9.5 Ki —
No preferred name
CHEMBL105819
 9.2 IC50 —
No preferred name
CHEMBL92615
 8.5 Ki —
No preferred name
CHEMBL290376
 8.2 Ki —
No preferred name
CHEMBL5901486
 8.2 IC50 —

Approved Drugs

Structure Compound First Approval
MELAGATRAN
CHEMBL266349
 2004
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-12T23:16:29Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1873